112 related articles for article (PubMed ID: 7581527)
21. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy.
Joudi FN; Smith BJ; O'Donnell MA; Konety BR
J Urol; 2006 May; 175(5):1634-9; discussion 1639-40. PubMed ID: 16600718
[TBL] [Abstract][Full Text] [Related]
22. Salvage combination intravesical immunotherapy with Bacillus Calmette-Guérin and interferon-α2B: impact on recurrence, progression, and survival.
Prasad SM; Eyre S; Loughlin KR
Hosp Pract (1995); 2013; 41(4):31-9. PubMed ID: 24145587
[TBL] [Abstract][Full Text] [Related]
23. [Results obtained by intravesical instillation of BCG in superficial bladder tumors].
Romics I; Dietmar B; Christoph R
Orv Hetil; 1990 Jan; 131(1):25-8. PubMed ID: 2405331
[TBL] [Abstract][Full Text] [Related]
24. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
Ding GQ; Shen ZJ; Lu J; Jin XD; Chen J; Shi SF
Zhonghua Wai Ke Za Zhi; 2005 Nov; 43(22):1457-60. PubMed ID: 16318813
[TBL] [Abstract][Full Text] [Related]
25. [Treatment of superficial bladder tumors with intravesical BCG vaccine].
Damianov Kh; Engibarov A; Patrashkov T; Tonchev T; Chuchkova M
Khirurgiia (Sofiia); 1988; 41(2):23-8. PubMed ID: 3411877
[No Abstract] [Full Text] [Related]
26. [A comparative clinical trial of UFT medication and intravesical BCG in the recurrence of superficial bladder cancer. Study Group of UFT and BCG adjuvant therapy for bladder cancer].
Oda H; Seki N; Nabeshima S; Oda T; Nishio S; Yokoyama M; Iwata H; Takeuchi M; Matsumoto A; Terado T
Gan To Kagaku Ryoho; 1990 Oct; 17(10):2051-5. PubMed ID: 2221929
[TBL] [Abstract][Full Text] [Related]
27. [Intravesical BCG therapy in patients with recurrent superficial bladder tumors].
Sugimoto M; Yamamoto H; Itakura H; Shinohara M; Kinoshita K
Gan To Kagaku Ryoho; 1989 Dec; 16(12):3725-8. PubMed ID: 2596855
[TBL] [Abstract][Full Text] [Related]
28. [Intravesical bacillus Calmette-Guerin in the treatment of recurrent superficial bladder tumors].
Nakano M; Iwamuro S; Fujii H; Kondoh I
Hinyokika Kiyo; 1988 Jun; 34(6):983-6. PubMed ID: 3223463
[TBL] [Abstract][Full Text] [Related]
29. [Effect of prophylactic intravesical instillation of BCG for superficial bladder cancer].
Segawa N; Inamoto T; Nomi H; Ibuki N; Azuma H; Katsuoka Y
Hinyokika Kiyo; 2009 Apr; 55(4):175-80. PubMed ID: 19462820
[TBL] [Abstract][Full Text] [Related]
30. [Bacillus Calmette Guerin as adjuvant treatment for superficial bladder tumors using two different therapeutic schemes].
Iturralde Codina A; Beyríe Tamayo W; Gozá León F; Muñoz YI
Arch Esp Urol; 2004; 57(6):606-18. PubMed ID: 15382436
[TBL] [Abstract][Full Text] [Related]
31. Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy.
Punnen SP; Chin JL; Jewett MA
Can J Urol; 2003 Apr; 10(2):1790-5. PubMed ID: 12773228
[TBL] [Abstract][Full Text] [Related]
32. Bladder cancer: current optimal intravesical treatment.
Lamm DL; McGee WR; Hale K
Urol Nurs; 2005 Oct; 25(5):323-6, 331-2. PubMed ID: 16294610
[TBL] [Abstract][Full Text] [Related]
33. [Role of BCG in T1G3 bladder transitional cell carcinoma (TCC): our experience].
Comeri GC; Belvisi P; Conti G; Cretarola E; Duvia R; Furgoni R; Gianneo E; Radice GP
Arch Ital Urol Androl; 1996 Feb; 68(1):55-9. PubMed ID: 8664924
[TBL] [Abstract][Full Text] [Related]
34. Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy.
Gallagher BL; Joudi FN; Maymí JL; O'Donnell MA
Urology; 2008 Feb; 71(2):297-301. PubMed ID: 18308107
[TBL] [Abstract][Full Text] [Related]
35. [Long-term results and complications of intravesical instillation of bacillus Calmette-Guerin for prophylaxis of bladder cancer recurrence].
Irie A; Lee KE; Kadowaki K; Sawamura M
Hinyokika Kiyo; 1994 Oct; 40(10):873-7. PubMed ID: 7992700
[TBL] [Abstract][Full Text] [Related]
36. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
Lamm D; Brausi M; O'Donnell MA; Witjes JA
Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
[TBL] [Abstract][Full Text] [Related]
37. Comparison of two doses of interferon-alpha-2b in intravesical prophylaxis of superficial bladder tumors. Portuguese Genito-Urinary Group.
da Silva FC; Furtado L; Reis M; Carreira F; Dias V; Oliveira G
Eur Urol; 1995; 28(4):291-6. PubMed ID: 8575495
[TBL] [Abstract][Full Text] [Related]
38. [Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer].
Yamada Y; Washida H; Tozawa K; Honma H; Kang K
Hinyokika Kiyo; 1994 Jul; 40(7):575-9. PubMed ID: 8085517
[TBL] [Abstract][Full Text] [Related]
39. A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy.
Mangiarotti B; Trinchieri A; Del Nero A; Montanari E
Arch Ital Urol Androl; 2008 Dec; 80(4):167-71. PubMed ID: 19235434
[TBL] [Abstract][Full Text] [Related]
40. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials.
Han RF; Pan JG
Urology; 2006 Jun; 67(6):1216-23. PubMed ID: 16765182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
